Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.
Ontology highlight
ABSTRACT: Stem cell transplantation and genetic therapies offer potential cures for patients with sickle cell disease (SCD), but these options require advanced medical facilities and are expensive. Consequently, these treatments will not be available for many years to the majority of patients suffering from this disease. What is urgently needed now is an inexpensive oral drug in addition to hydroxyurea, the only drug approved by the FDA that inhibits sickle-hemoglobin polymerization. Here, we report the results of the first phase of our phenotypic screen of the 12,657 compounds of the Scripps ReFRAME drug repurposing library using a recently developed high-throughput assay to measure sickling times following deoxygenation to 0% oxygen of red cells from sickle trait individuals. The ReFRAME library i
SUBMITTER: Metaferia B
PROVIDER: S-EPMC9546543 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA